var data={"title":"Colistin (colistimethate): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Colistin (colistimethate): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5944?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=colistin-colistimethate-patient-drug-information\" class=\"drug drug_patient\">see &quot;Colistin (colistimethate): Patient drug information&quot;</a> and <a href=\"topic.htm?path=colistin-colistimethate-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Colistin (colistimethate): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154558\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Coly-Mycin M</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154559\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Coly-Mycin M</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154573\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antibiotic, Miscellaneous</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154561\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Dosage expressed in terms of mg of <b>colistin base activity (CBA). CBA 1 mg </b>is defined to be equivalent to <b>colistimethate sodium (CMS) 30,000 units</b> which is equivalent to <b>~2.4 mg CMS</b> (EMA 2014; Falagas 2006; Kassamali 2013; Nation 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Susceptible infections: </b>IM, IV: 2.5 to 5 mg CBA/kg/day in 2 to 4 divided doses; maximum: 5 mg/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Severe infections (due to multidrug-resistant organisms susceptible to colistin in the critically ill) (off-label dosing): </b>IV: Loading dose: 300 mg CBA followed by 150 mg CBA twice daily (Dalfino 2012; Plachouras 2009). Additional trials may be necessary to further evaluate the use of this dosing in critically ill patients with this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">May also consider using the following calculations; however, although derived from critically ill patients, the use of this algorithm has not been prospectively evaluated in the critically ill (Garonzik 2011):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Loading dose of colistin base activity (mg)</i> = Target average colistin steady-state plasma concentration (in mg/L) x 2 x weight (in kg). For patient weight, use the lower of ideal or actual body weight expressed in kg. In obese patients, application of these equations has not been evaluated.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Daily maintenance dose of colistin base activity (mg)</i> = Target average colistin steady-state plasma concentration (in mg/L) x ([1.5 x CrCl] + 30). <b>See dosing in renal impairment for frequency of administration based on CrCl.</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> Do not exceed a total daily dose of 300 mg CBA (according to this algorithm). Unless it is appropriate to target a low colistin steady-state plasma concentration (C<sub>ss,avg</sub>), the authors do not recommended the use of these calculations in patients with CrCl &gt;70 mL/minute/1.73 m<sup>2</sup>, in which case the loading dose or the daily maintenance dose may be substantially greater than 300 mg CBA. Use caution with loading doses &gt;300 mg CBA. Target C<sub>ss,avg</sub> is typically 2.5 mg/L (range: 2 to 4 mg/L [Couet 2012]) and should be based on MIC, site, and severity of infection. CrCl is expressed in mL/minute/1.73 m<sup>2</sup>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bronchiectasis, pulmonary colonization/infection with susceptible organisms in patients with cystic fibrosis and noncystic fibrosis (off-label use/route):</b> Inhalation: 30 to 150 mg CBA via nebulizer 1 to 3 times daily (maximum dose: 150 mg 2 times daily) (Le 2010; Sabuda 2008; Steinfort 2007). <b>Note:</b> An optimal dosing regimen has not been determined and varies widely among studies; lower doses have been used in noncystic fibrosis patients with bronchiectasis (Steinfort 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cystic fibrosis (off-label use):</b> IV: 3 mg CBA/kg/day in 3 divided doses (Young 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Meningitis (susceptible gram-negative organisms):</b> Intrathecal/intraventricular (off-label route): 4.2 mg CBA/day (equivalent to 10 mg CMS/day) (IDSA [Tunkel 2017]; Imberti 2012; Ziaka 2013); <b>Note:</b> Dose in clinical reports has ranged from 0.7 to 8.3 mg CBA/day in 1 or 2 divided doses (administered with concomitant systemic antimicrobial therapy) (Benifla 2004; Falagas 2007; Imberti 2012; Katragkou 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pneumonia, hospital-acquired or ventilator-associated due to susceptible multidrug-resistant gram-negative bacilli (eg, <i>Pseudomonas aeruginosa</i>, <i>Acinetobacter spp</i>) (off-label):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Nebulization (via ventilator circuit): 150 mg CBA every 8 hours delivered over 60 minutes for 14 days or until successful wean from mechanical ventilation (treatment duration range: 7 to 19 days) (Lu 2012). May consider using as an adjunct in patients receiving IV colistin; may improve clinical outcomes (Doshi 2013; Tumbarello 2013; Valachis 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: Loading dose: 5 mg CBA/kg/dose for 1 dose (use the lower of ideal or actual body weight), followed by a maintenance dose beginning 24 hours following the loading dose; the daily maintenance dose (in mg) may be calculated by multiplying 2.5 by (1.5 x CrCl + 30) and administered in divided doses every 8 to 12 hours based on CrCl (see Dosing: Renal Impairment) (Garonzik 2011). Caution is advised when administering doses &gt;300 mg CBA/day (single loading doses or total maintenance daily doses) due to limited experience; therefore, the maintenance dose algorithm should be used with caution in patients with moderate-to-good renal function and is not recommended for use in patients with CrCl &gt;70 mL/minute/1.73 m<sup>2</sup> (Garonzik 2011). Consider using adjunctive inhaled colistin. When used for empiric treatment of ventilator-associated pneumonia, use in combination with an agent with MRSA activity (or MSSA activity, if appropriate), with or without an additional antipseudomonal agent (dependent on risk factors) (Kalil 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154569\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=colistin-colistimethate-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Colistin (colistimethate): Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Dosage expressed in terms of <b>colistin base activity (CBA); </b>although reported conversions have varied slightly in the literature,<b> CBA 1 mg </b>is defined to be equivalent to <b>colistimethate sodium (CMS) 30,000 units, </b>which is equivalent to <b>~2.4 mg</b> <b>CMS</b> (EMA 2014; Falagas 2006; Kassamali 2013; Nation 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Susceptible infections: </b>IM, IV: 2.5 to 5 mg CBA/kg/day in 2 to 4 divided doses; maximum: 5 mg/kg/day</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154562\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154563\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Dosage expressed in terms of <b>colistin base activity (CBA);</b> although reported conversions have varied slightly in the literature,<b> CBA 1 mg </b>is defined to be equivalent to<b> colistimethate sodium (CMS) 30,000 units</b> (Falagas 2006).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IM, IV: Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Manufacturer's labeling:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &ge;80 mL/minute: No dosage adjustment necessary; maximum: 5 mg CBA/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 50 to 79 mL/minute: 2.5 to 3.8 mg CBA/kg/day in 2 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 30 to 49 mL/minute: 2.5 mg CBA/kg/day once daily or in 2 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 10 to 29 mL/minute: 1.5 mg CBA/kg every 36 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Alternative recommendations:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Severe infections (due to multidrug-resistant organisms susceptible to colistin in the critically ill) (Dalfino 2012): <b>Note:</b> CrCl calculated using the Cockcroft-Gault equation. IV:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &ge;50 mL/minute: Loading dose of 300 mg CBA followed by 150 mg CBA twice daily.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 20 to 50 mL/minute: Loading dose of 300 mg CBA followed by 150 mg CBA once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &lt;20 mL/minute: Loading dose of 300 mg CBA followed by 150 mg CBA every 48 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">May also consider using the following calculations; however, although derived from critically ill patients, the use of this algorithm has not been prospectively evaluated in the critically ill (Garonzik 2011):</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Loading dose of colistin base activity (mg)</i> = Target average colistin steady-state plasma concentration (in mg/L) x 2 x weight (in kg). For patient weight, use the lower of ideal or actual body weight expressed in kg. In obese patients, application of these equations has not been evaluated.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Daily maintenance dose of colistin base activity (mg)</i> = Target average colistin steady-state plasma concentration (in mg/L) x ([1.5 x CrCl] + 30)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <b>Note:</b> Use caution with loading doses &gt;300 mg CBA. Do not exceed a total daily dose of 300 mg CBA (according to this algorithm). Target C<sub>ss,avg</sub> is typically 2.5 mg/L but may range from 2 to 4 mg/L (Couet 2012). Calculate CrCl using the Jellife method mL/minute/1.73 m<sup>2</sup> or the Cockcroft-Gault method (normalized to BSA of 1.73 m<sup>2</sup>).</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">CrCl &gt;70 mL/minute/1.73 m<sup>2</sup>: Administer calculated daily maintenance dose in 2 to 3 divided doses every 12 or 8 hours, respectively. <b>Note:</b> Unless it is appropriate to target a low colistin C<sub>ss,avg</sub>, the authors do not recommended the use of these calculations in patients with CrCl &gt;70 mL/minute/1.73 m<sup>2</sup>.</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">CrCl 10 to 70 mL/minute/1.73 m<sup>2</sup>: Administer calculated daily maintenance dose in 2 to 3 divided doses every 12 or 8 hours, respectively.</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">CrCl &lt;10 mL/minute/1.73 m<sup>2</sup>: Administer calculated daily maintenance dose in divided doses every 12 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intermittent hemodialysis (IHD) (administer after hemodialysis on dialysis days): IV: 1.5 mg CBA/kg every 24 to 48 hours (Heintz 2009). <b>Note:</b> Dosing dependent on the assumption of 3 times/week, complete IHD sessions. Alternatively, may administer a daily dose of 30 mg CBA for every 1 mg/L colistin C<sub>ss,avg</sub> target given in divided doses every 12 hours on nonhemodialysis days. For example, if the C<sub>ss,avg</sub> target is 2.5 mg/L, then administer 37.5 mg CBA every 12 hours on nonhemodialysis days. On hemodialysis days (ideally performed at the end of the colistin dosage interval), administer a supplemental dose of 50% of the total daily dose if the supplemental dose is administered during the last half hour of the hemodialysis session <b>or</b> 30% of the total daily dose if the supplemental dose is administered after the hemodialysis session. These recommendations, although derived from critically ill patients, have not been prospectively evaluated in the critically ill (Garonzik 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Continuous renal replacement therapy (CRRT) (Heintz 2009; Trotman 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate). The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1 to 2 L/hour and minimal residual renal function) and should not supersede clinical judgment:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CVVH/CVVHD/CVVHDF: IV: 2.5 mg CBA/kg every 24 to 48 hours (frequency dependent upon site or severity of infection or susceptibility of pathogen). Alternatively, in patients receiving CVVH or CVVHD, may administer a daily dose of 192 mg CBA for every 1 mg/L colistin C<sub>ss,avg</sub> target given in 2 to 3 equally divided doses every 12 or 8 hours, respectively (Garonzik 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> A single case report has demonstrated that the use of 2.5 mg CBA/kg every 48 hours with a dialysate flow rate of 1 L/hour may be inadequate and that dosing every 24 hours was well-tolerated. Based on pharmacokinetic analysis, the authors recommend dosing as frequent as every 12 hours in patients receiving CVVHDF (Li 2005).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15795898\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20330556\" class=\"block doo drugH1Div\"><span class=\"drugH1\">Dosing: Obesity</span>\n    <p style=\"text-indent:0em;display:inline\">Doses should be based on ideal body weight in obese patients.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F18881845\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">CNS toxicity: Dose reduction may reduce neurologic symptoms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Nephrotoxicity: Withhold treatment if signs of renal impairment occur during treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154544\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection [strength expressed as base, preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Coly-Mycin M: 150 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 150 mg (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154532\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154546\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Parenteral: Administer by IM, direct IV injection over 3 to 5 minutes, intermittent infusion over 30 minutes (Beringer 2001; Conway, 1997), or by continuous IV infusion (according to the manufacturer). For continuous IV infusion, one-half of the total daily dose is administered by direct IV injection over 3 to 5 minutes followed 1 to 2 hours later by the remaining one-half of the total daily dose diluted in a compatible IV solution infused over 22 to 23 hours. The final concentration for continuous infusion administration should be based on the patient's fluid needs; infusion should be completed within 24 hours of preparation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Inhalation (off-label route): Administer solution via nebulizer (vibrating plate nebulizer may be preferred [Lu 2012]) promptly following preparation to decrease possibility of high concentrations of colistin from forming which may lead to potentially life-threatening lung toxicity. Consider use of a bronchodilator (eg, albuterol) within 15 minutes prior to administration (Le 2010). If patient is on a ventilator, place medicine in a T-piece at the midinspiratory circuit of the ventilator. One study in adult patients with VAP administered colistimethate over 60 minutes using a vibrating plate nebulizer positioned on the inspiratory limb 10 cm proximal to the Y-piece (Lu 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Note:</b> A case report of fatal lung toxicity implicated <i>in vitro</i> colistin formation from an inhalation solution as a potential etiology, but data regarding the concentration, formulation and storage of the inhaled colistin administered to the patient were not reported (FDA 2007; McCoy 2007; Wallace 2008). An acceptable limit of <i>in vitro</i> colistin formation to prevent potential toxicity is unknown. Limited stability data are available regarding the storage of colistin solution for inhaled administration (Healan 2012; Wallace 2008). Storing for &gt;24 hours may increase the risk for potential lung toxicity; preparation immediately prior to administration is recommended (FDA  2007; Le 2010, Wallace 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Intrathecal/intraventricular (off-label route): Administer only preservative-free solutions via intrathecal/intraventricular routes. Administer promptly after preparation. Discard unused portion of vial.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154545\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli (particularly <i>Pseudomonas aeruginosa</i>) which are resistant to other antibacterials or in patients allergic to other antibacterials</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25475254\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Non-ventilator associated pneumonia (non-VAP) infections (nebulized; off-label route); Ventilator-associated pneumonia (VAP) due to multidrug-resistant Pseudomonas aeruginosa or Acinetobacter baumannii (nebulized; off-label route); Bronchiectasis, pulmonary colonization/infection with susceptible organisms in patients with cystic fibrosis and noncystic fibrosis; Prevention of Pseudomonas aeruginosa respiratory tract infections in immunocompromised patients (nebulized inhalation); Adjunct agent (nebulized inhalation) for the treatment of P. aeruginosa infections in patients with cystic fibrosis and other seriously ill or chronically ill patients</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14219656\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Due to the potential for dosing errors, it is recommended that prescriptions for colistimethate be expressed as colistin base activity only.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154539\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Nephrotoxicity (18% to 26% [Dalfino 2012; Oliveira 2009])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Acute renal failure (33% to 60% [Akajagbor 2013; Deryke 2010])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Neurotoxicity (7%; higher incidence with high-dose IV use in cystic fibrosis [Bosso 1991; Koch-Weser 1970])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness, oral paresthesia, paresthesia, peripheral paresthesia, seizures, slurred speech, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Pruritus, skin rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Clostridium difficile associated diarrhea, gastric distress</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Decreased urine output</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Anaphylaxis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Decreased creatinine clearance, increased blood urea nitrogen, increased serum creatinine</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Apnea, respiratory distress</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154549\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to colistimethate, colistin, or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154536\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Bronchoconstriction: Use of inhaled colistimethate (off-label route) may result in bronchoconstriction. Use with caution in patients with hyperactive airways; consider administration of a bronchodilator (eg, albuterol) within 15 minutes prior to administration (Le 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; CNS toxicity: Transient, reversible neurological disturbances (eg, dizziness, numbness, paresthesia, generalized pruritus, slurred speech, tingling, vertigo) may occur. Patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Dose reduction may reduce neurologic symptoms; monitor closely.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal toxicity: Dose-dependent nephrotoxicity has been reported, generally reversible upon discontinuation of treatment. Withhold treatment if signs of renal impairment occur during treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Respiratory arrest: Respiratory arrest has been reported with use; impaired renal function may increase the risk for neuromuscular blockade and apnea.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with preexisting renal impairment; dosage adjustments are recommended. Impaired renal function may increase the risk for respiratory arrest.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: Inhalation (off-label route):  Once mixed, colistimethate begins conversion to bioactive colistin, a component of which may result in severe pulmonary toxicity (Le 2010). Solutions for inhalation must be mixed immediately prior to administration and used within 24 hours to reduce the incidence of pulmonary toxicity. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: IV: Use only to prevent or treat infections strongly suspected or proven to be caused by susceptible bacteria to minimize development of bacterial drug resistance.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Safety: Potential for dosing errors due to lack of standardization in literature when referring to product and dose; colistimethate (inactive prodrug) and colistin base strengths are not interchangeable; verify prescribed dose is expressed in terms of colistin base activity prior to dispensing. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299084\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154540\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8718&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides: May enhance the nephrotoxic effect of Colistimethate. Aminoglycosides may enhance the neuromuscular-blocking effect of Colistimethate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphotericin B: May enhance the nephrotoxic effect of Colistimethate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bacitracin (Systemic): Colistimethate may enhance the nephrotoxic effect of Bacitracin (Systemic). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capreomycin: May enhance the neuromuscular-blocking effect of Colistimethate.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cefazedone: May enhance the nephrotoxic effect of Colistimethate.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephalothin: May enhance the nephrotoxic effect of Colistimethate.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mecamylamine: Colistimethate may enhance the neuromuscular-blocking effect of Mecamylamine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methoxyflurane: Colistimethate may enhance the nephrotoxic effect of Methoxyflurane. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular-Blocking Agents: Colistimethate may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Polymyxin B: May enhance the neuromuscular-blocking effect of Colistimethate.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vancomycin: May enhance the nephrotoxic effect of Colistimethate.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154542\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5105300\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. Colistimethate crosses the placenta in humans.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5105303\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Colistin (the active form of colistimethate sodium) and colistin sulphate (another form of colistin) are excreted in human milk. The manufacturer recommends caution if giving colistimethate sodium to a breast-feeding woman. Nondose-related effects could include modification of bowel flora. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5105494\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Serum creatinine, BUN; urine output; signs of neurotoxicity; signs of bronchospasm (inhalation [off-label route])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154535\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Colistimethate (or the sodium salt [colistimethate sodium]) is the inactive prodrug that is hydrolyzed to colistin, which acts as a cationic detergent and damages the bacterial cytoplasmic membrane causing leaking of intracellular substances and cell death</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154548\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Not absorbed from the GI tract, mucous membranes, or intact skin (<b>Note:</b> GI absorption has been observed in infants).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Distributes widely, except for CNS, synovial, pleural, and pericardial fluids</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Healthy volunteer:</i> IV: Colistimethate: V<sub>d</sub>: 8.92 L; Colistin: V<sub>d</sub>: 12.4 L (Couet 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Critically ill:</i> IV: Colistimethate: V<sub>d</sub>: 5.3 to 13.5 L; Colistin: V<sub>d</sub>: 7.2 to 189 L (Couet 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Cystic fibrosis:</i> Adolescents and Adults: IV: Colistimethate: V<sub>dss</sub>: 0.09 &plusmn; 0.03 L/kg (Reed 2001)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 50%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Colistimethate sodium (inactive prodrug) is hydrolyzed to colistin (active form). <b>Note:</b> Only ~30% of colistimethate sodium is converted to colistin (Couet 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: IM, IV: Colistimethate: 2 to 3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Critically ill:</i> Infants (including premature infants), Children, Adolescents, and Adults: IV: Colistimethate: 2.3 hours; Colistin: 14.4 hours (Plachouras 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Cystic fibrosis:</i> IV: Colistin: ~4 hours (Li 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>ESRD patients receiving CAPD:</i> IV: Colistin: 13.2 hours (Koomanachai 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Healthy volunteers:</i> IV: Colistin: 2 hours (range: 1 to 4 hours) (Couet 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Critically ill:</i> IV: Colistin: ~7 hours (Plachouras 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Primarily urine (as unchanged drug)); most colistin recovered in the urine is from postexcretion hydrolysis of colistimethate sodium (Couet 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323078\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Colistimethate Sodium Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (1): $33.60</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Coly-Mycin M Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (1): $33.60</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038587\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Acostin (IN);</li>\n      <li>Aldreb (JP);</li>\n      <li>Alficetin (AR);</li>\n      <li>Alveoxina (AR);</li>\n      <li>Avagal (UY);</li>\n      <li>Colfinair (ES);</li>\n      <li>Colifin (CH, DE);</li>\n      <li>Colimex (LI, QA, SA);</li>\n      <li>Colimicina (IT);</li>\n      <li>Colimycin (CL);</li>\n      <li>Colimycine (FR, SK);</li>\n      <li>Coliracin (IL);</li>\n      <li>Colis (KR);</li>\n      <li>Colistate (TH);</li>\n      <li>Colistimixin (AU);</li>\n      <li>Colistin (CH, HK, NL, PL);</li>\n      <li>Colistin Link (AU, NZ);</li>\n      <li>Colistineb (BE);</li>\n      <li>Colixin (PT);</li>\n      <li>Colmesdant (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Colobreathe (BE, CZ, EE, ES, GB, HU, IE, LT, NL, PL, SE);</li>\n      <li>Colomycin (CZ, GB, GR, HK, HN, IE, MY, SG, SI);</li>\n      <li>Costim (TW);</li>\n      <li>Damacol (LI);</li>\n      <li>Eskcolis (BD);</li>\n      <li>Kolneb (AT);</li>\n      <li>Kolomitsyn (UA);</li>\n      <li>Kolomycin (SK);</li>\n      <li>Mellistin (TH);</li>\n      <li>Promixin (DE, DK, ES, GB, IE, NO);</li>\n      <li>Tadim (AU, GR, NL, SE);</li>\n      <li>Xylistin (IN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Akajagbor DS, Wilson SL, Shere-Wolfe KD, Dakum P, Charurat ME, Gilliam BL. Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center. <i>Clin Infect Dis</i>. 2013;57(9):1300-1303.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-drug-information/abstract-text/23840000/pubmed\" target=\"_blank\" id=\"23840000\">23840000</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alothman GA, Ho B, Alsaadi MM, et al, &ldquo;Bronchial Constriction and Inhaled Colistin in Cystic Fibrosis,&rdquo; <i>Chest</i>, 2005, 127(2):522-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-drug-information/abstract-text/15705991/pubmed\" target=\"_blank\" id=\"15705991\">15705991</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bauldoff GS, Nunley DR, Manzetti JD, et al, &ldquo;Use of Aerosolized Colistin in Cystic Fibrosis Patients Awaiting Lung Transplantation,&rdquo; <i>Transplantation</i>, 1997, 64(5):748-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-drug-information/abstract-text/9311714/pubmed\" target=\"_blank\" id=\"9311714\">9311714</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15190037\"></a>Benifla M, Zucker G, Cohen A, Alkan M. Successful treatment of Acinetobacter meningitis with intrathecal polymyxin E. <i>J Antimicrob Chemother</i>. 2004;54(1):290-292. doi: 10.1093/jac/dkh289.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-drug-information/abstract-text/15190037/pubmed\" target=\"_blank\" id=\"15190037\">15190037</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Beringer P, &ldquo;The Clinical Use of Colistin in Patients With Cystic Fibrosis,&rdquo; <i>Curr Opin Pulm Med</i>, 2001, 7(6):434-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-drug-information/abstract-text/11706322/pubmed\" target=\"_blank\" id=\"11706322\">11706322</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berlana D, Llop JW, Fort E. Badia MB, J&oacute;dar R. Use of colistin in the treatment of multiple-drug-resistant gram-negative infections. <i>Am J Health-Syst Pharm</i>. 2005;62(1):39-47.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-drug-information/abstract-text/15658071/pubmed\" target=\"_blank\" id=\"15658071\">15658071</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bosso JA, Liptak CA, Seilheimer DK, et al, &ldquo;Toxicity of Colistin in Cystic Fibrosis Patients,&rdquo; <i>DICP</i>, 1991, 25(11):1168-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-drug-information/abstract-text/1763528/pubmed\" target=\"_blank\" id=\"1763528\">1763528</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Coly-Mycin M prescribing information, JHP Pharmaceuticals, LLC, Rochester, MI, January 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Conway SP, Pond MN, Watson A, et al, &ldquo;Intravenous Colistin Sulphomethate in Acute Respiratory Exacerbations in Adult Patients With Cystic Fibrosis,&rdquo; <i>Thorax</i>, 1997, 52(11):987-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-drug-information/abstract-text/9487348/pubmed\" target=\"_blank\" id=\"9487348\">9487348</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Couet W, Gr&eacute;goire N, Marchand S, Mimoz O. Colistin pharmacokinetics: the fog is lifting. <i>Clin Microbiol Infect</i>. 2012;18(1):30-39.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-drug-information/abstract-text/21988234/pubmed\" target=\"_blank\" id=\"21988234\">21988234</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Couet W, Gr&eacute;goire N, Gobin P, et al. Pharmacokinetics of colistin and colistimethate sodium after a single 80-mg intravenous dose of CMS in young healthy volunteers. <i>Clin Pharmacol Ther</i>. 2011;89(6):875-879.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-drug-information/abstract-text/21544080/pubmed\" target=\"_blank\" id=\"21544080\">21544080</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dalfino L, Puntillo F, Mosca A, et al. High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study. <i>Clin Infect Dis</i>. 2012;54(12):1720-1726.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-drug-information/abstract-text/22423120/pubmed\" target=\"_blank\" id=\"22423120\">22423120</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Deryke CA, Crawford AJ, Uddin N, Wallace MR. Colistin dosing and nephrotoxicity in a large community teaching hospital. <i>Antimicrob Agents Chemother</i>. 2010;54(10):4503-4505.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-drug-information/abstract-text/20660694/pubmed\" target=\"_blank\" id=\"20660694\">20660694</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Doshi NM, Cook CH, Mount KL, et al. Adjunctive aerosolized colistin for multi-drug resistant gram-negative pneumonia in the critically ill: a retrospective study. <i>BMC Anesthesiology</i>. 2013;13(1):45.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-drug-information/abstract-text/24274315/pubmed\" target=\"_blank\" id=\"24274315\">24274315</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    European Medicine Agency (EMA). European Medicines Agency completes review of polymyxin-based medicine. Published October 24, 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    EMC Web site. Colomycin Injection. https://www.medicines.org.uk/emc/medicine/1590. Accessed December 19, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16723606\"></a>Falagas ME, Kasiakou SK. Use of international units when dosing colistin will help decrease confusion related to various formulations of the drug around the world. <i>Antimicrob Agents Chemother</i>. 2006;50(6):2274-2275.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-drug-information/abstract-text/16723606/pubmed\" target=\"_blank\" id=\"16723606\">16723606</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17126534\"></a>Falagas ME, Bliziotis IA, Tam VH. Intraventricular or intrathecal use of polymyxins in patients with Gram-negative meningitis: a systematic review of the available evidence. <i>Int J Antimicrob Agents</i>. 2007;29(1):9-25. doi: 10.1016/j.ijantimicag.2006.08.024.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-drug-information/abstract-text/17126534/pubmed\" target=\"_blank\" id=\"17126534\">17126534</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Garonzik SM, Li J, Thamlikitkul V, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. <i>Antimicrob Agents Chemother</i>. 2011;55(7):3284-3294.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-drug-information/abstract-text/21555763/pubmed\" target=\"_blank\" id=\"21555763\">21555763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heintz BH, Matzke GR, Dager WE, &ldquo;Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,&rdquo; <i>Pharmacotherapy</i>, 2009, 29(5):562-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-drug-information/abstract-text/19397464/pubmed\" target=\"_blank\" id=\"19397464\">19397464</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Honore PM, Jacobs R, Hendrickx I, De Waele E, De Regt J, Spapen HD.. Nebulized colistin for treatment of ventilator-associated pneumonia caused by multidrug-resistant Gram-negative bacteria: we still need to straighten out the dose! <i>Crit Care</i>. 2015;19:265.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-drug-information/abstract-text/26113262/pubmed\" target=\"_blank\" id=\"26113262\">26113262</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22687507\"></a>Imberti R, Cusato M, Accetta G, et al. Pharmacokinetics of colistin in cerebrospinal fluid after intraventricular administration of colistin methanesulfonate. <i>Antimicrob Agents Chemother</i>. 2012;56(8):4416-4421. doi: 10.1128/AAC.00231-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-drug-information/abstract-text/22687507/pubmed\" target=\"_blank\" id=\"22687507\">22687507</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jensen T, Pederson SS, Garne S, et al, &ldquo;Colistin Inhalation Therapy in Cystic Fibrosis Patients With Chronic <i>Pseudomonas aeruginosa</i> Lung Infection,&rdquo; <i>J Antimicrob Chemother</i>, 1987, 19(6):831-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-drug-information/abstract-text/3301785/pubmed\" target=\"_blank\" id=\"3301785\">3301785</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society [published online July 14, 2016]. <i>Clin Infect Dis</i>. doi: 10.1093/cid/ciw353.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-drug-information/abstract-text/27418577/pubmed\" target=\"_blank\" id=\"27418577\">27418577</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kassamali Z, Jain R, Danziger LH. An update on the arsenal for multidrug-resistant Acinetobacter infections: polymyxin antibiotics. <i>Int J Infect Dis</i>. 2015;30:125-132. doi: 10.1016/j.ijid.2014.10.014.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-drug-information/abstract-text/25461655/pubmed\" target=\"_blank\" id=\"25461655\">25461655</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23728146\"></a>Kassamali Z, Rotschafer JC, Jones RN, Prince RA, Danziger LH. Polymyxins: wisdom does not always come with age. <i>Clin Infect Dis</i>. 2013;57(6):877-83. doi: 10.1093/cid/cit367.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-drug-information/abstract-text/23728146/pubmed\" target=\"_blank\" id=\"23728146\">23728146</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Katragkou A and Roilides E, &ldquo;Successful Treatment of Multidrug-Resistant <i>Acinetobacter baumannii</i> Central Nervous System Infections With Colistin,&rdquo; <i>J Clin Microbiol</i>, 2005, 43(9):4916-17.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-drug-information/abstract-text/16145177/pubmed\" target=\"_blank\" id=\"16145177\">16145177</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Koch-Weser J, Sidel VW, Federman EB, Kanarek P, Finer DC, Eaton AE. Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy. <i>Ann Intern Med</i>. 1970;72(6):857-868.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-drug-information/abstract-text/5448745/pubmed\" target=\"_blank\" id=\"5448745\">5448745</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Koerner-Rettberg C, Ballman M. Colistimethate sodium for the treatment of chronic pulmonary infection in cystic fibrosis: an evidence-based review of its place in therapy. <i>Core Evid</i>. 2014;9:99-112.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-drug-information/abstract-text/25278817/pubmed\" target=\"_blank\" id=\"25278817\">25278817</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Koomanachai P, Landersdorfer CB, Chen G, et al. Pharmacokinetics of colistin methanesulfonate and formed colistin in end-stage renal disease patients receiving continuous ambulatory peritoneal dialysis. <i>Antimicrob Agents Chemother</i>. 2014;58(1):440-446.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-drug-information/abstract-text/24189256/pubmed\" target=\"_blank\" id=\"24189256\">24189256</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Landersdorfer CB, Nation RL. Colistin: How should it be dosed for the critically ill? <i>Semin Respir Crit Care Med</i>. 2015;36:126-135.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-drug-information/abstract-text/25643276/pubmed\" target=\"_blank\" id=\"25643276\">25643276</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Le J, Ashley ED, Neuhauser MM, et al, &ldquo;Consensus Summary of Aerosolized Antimicrobial Agents: Application of Guideline Criteria,&rdquo; <i>Pharmacotherapy</i>, 2010, 30(6):562-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-drug-information/abstract-text/20500046/pubmed\" target=\"_blank\" id=\"20500046\">20500046</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Li J, Nation RL, Turnidge JD, et al. Colistin: the re-emerging antibiotic for multidrug-resistant gram-negative bacterial infections. <i>Lancet Infect Dis</i>. 2006;6(9):589-601.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-drug-information/abstract-text/16931410/pubmed\" target=\"_blank\" id=\"16931410\">16931410</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Li J, Rayner CR, Nation RL, et al, &ldquo;Pharmacokinetics of Colistin Methanesulfonate and Colistin in a Critically Ill Patient Receiving Continuous Venovenous Hemodiafiltration,&rdquo; <i>Antimicrob Agents Chemother</i>, 2005, 49(11):4814-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-drug-information/abstract-text/16251342/pubmed\" target=\"_blank\" id=\"16251342\">16251342</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lim LM, Ly N, Anderson D, et al, &ldquo;Resurgence of Colistin: A Review of Resistance, Toxicity, Pharmacodynamics, and Dosing,&rdquo; <i>Pharmacotherapy</i>, 2010, 30(12):1279-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-drug-information/abstract-text/21114395/pubmed\" target=\"_blank\" id=\"21114395\">21114395</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23132092\"></a>Lu Q, Luo R, Bodin L, et al, &ldquo;Efficacy of High-Dose Nebulized Colistin In Ventilator-Associated Pneumonia Caused By Multidrug-Resistant <i>Pseudomonas aeruginosa</i> and <i>Acinetobacter baumannii</i>,&rdquo; <i>Anesthesiology</i>, 2012, 117(6):1335-47.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-drug-information/abstract-text/23132092/pubmed\" target=\"_blank\" id=\"23132092\">23132092</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Maskin LP, Setten M, Rodriguez PO, et al. Inhaled colistimethate sodium in ventilator-associated tracheobronchitis due to multidrug-resistant Gram-negative bacteria. <i>Int J Antimicrob Agents</i>. 2015;45(2):199-200.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-drug-information/abstract-text/25459739/pubmed\" target=\"_blank\" id=\"25459739\">25459739</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McCoy KS. Compounded colistimethate as possible cause of fatal acute respiratory distress syndrome. <i>N Engl J Med</i>. 2007;357(22):2310-2311.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-drug-information/abstract-text/18046039/pubmed\" target=\"_blank\" id=\"18046039\">18046039</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Michalopoulos A, Fotakis D, Virtzili S, et al. Aerosolized coilistin as adjunctive treatment of ventilator-associate pneumonia due to multidrug-resistant Gram-negative bacteria: a prospective study [published online ahead of print December 3, 2007]. <i>Respir Med</i>. 2008;102(3):407-412.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-drug-information/abstract-text/18060758/pubmed\" target=\"_blank\" id=\"18060758\">18060758</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Moiraghi A and Moiraghi P, &quot;Colistin in Organic Fluids,&quot; In, Herold M, Gabriel Z, eds. <i>Antibiotics: Advances in Research, Production and Clinical Use; Proceedings of the Congress on Antibiotics Held in Prague, 15-19 June, 1964</i>, London, Butterworths, 1966;188-92.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"28011614\"></a>Nation RL, Garonzik SM, Thamlikitkul V, et al. Dosing guidance for intravenous colistin in critically-ill patients. <i>Clin Infect Dis</i>. 2017;64(5):565-571. doi: 10.1093/cid/ciw839.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-drug-information/abstract-text/28011614/pubmed\" target=\"_blank\" id=\"28011614\">28011614</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24107410\"></a>Nation RL, Li J, Cars O, et al. Consistent global approach on reporting of colistin doses to promote safe and effective use. <i>Clin Infect Dis.</i> 2014;58(1):139-141.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-drug-information/abstract-text/24107410/pubmed\" target=\"_blank\" id=\"24107410\">24107410</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Oliveira MS, Prado GV, Costa SF, Grinbaum RS, Levin AS. Polymyxin B and colistimethate are comparable as to efficacy and renal toxicity. <i>Diagn Microbiol Infect Dis</i>. 2009;65(4):431-434.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-drug-information/abstract-text/19733029/pubmed\" target=\"_blank\" id=\"19733029\">19733029</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Plachouras D, Karvanen M, Friberg LE, et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. <i>Antimicrob Agents Chemother</i>. 2009;53(8):3430-3436.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-drug-information/abstract-text/19433570/pubmed\" target=\"_blank\" id=\"19433570\">19433570</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Quinn AL, Parada JP, Belmares J, et al, &ldquo;Intrathecal Colistin and Sterilization of Resistant <i>Pseudomonas aeruginosa</i> Shunt Infection,&rdquo; <i>Ann Pharmacother</i>, 2005, 39(5):949-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-drug-information/abstract-text/15811909/pubmed\" target=\"_blank\" id=\"15811909\">15811909</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reed MD, Stern RC, O'Riordan MA, et al, &ldquo;The Pharmacokinetics of Colistin in Patients With Cystic Fibrosis,&rdquo; <i>J Clin Pharmacol</i>, 2001, 41(6):645-54.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-drug-information/abstract-text/11402633/pubmed\" target=\"_blank\" id=\"11402633\">11402633</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19436571\"></a>Sabuda DM, Laupland K, Pitout J, et al, &ldquo;Utilization of Colistin for Treatment of Multidrug-Resistant <i>Pseudomonas aeruginosa</i>,&rdquo; <i>Can J Infect Dis Med Microbiol</i>, 2008, 19(6):413-18.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-drug-information/abstract-text/19436571/pubmed\" target=\"_blank\" id=\"19436571\">19436571</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17547727\"></a>Steinfort DP and Steinfort C, &quot;Effect of Long-Term Nebulized Colistin on Lung Function and Quality of Life in Patients With Chronic Bronchial Sepsis,&quot; <i>Intern Med J</i>, 2007, 37(7):495-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-drug-information/abstract-text/17547727/pubmed\" target=\"_blank\" id=\"17547727\">17547727</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America [published online June 18, 2014]. <i>Clin Infect Dis</i>. 2014;59(2):e10-52. doi: 10.1093/cid/ciu296.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-drug-information/abstract-text/24947530/pubmed\" target=\"_blank\" id=\"24947530\">24947530</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trotman RL, Williamson JC, Shoemaker DM, et al, &ldquo;Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy,&rdquo; <i>Clin Infect Dis</i>, 2005, 41(8):1159-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-drug-information/abstract-text/16163635/pubmed\" target=\"_blank\" id=\"16163635\">16163635</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tumbarello M, De Pacale G, Trecarichi EM, et al. Effect of aerosolized colistin as adjunctive treatment on the outcomes of microbiologically documented ventilator-associated pneumonia caused by colistin-only susceptible gram-negative bacteria. <i>Chest</i>. 2013;144(6):1768-1775.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-drug-information/abstract-text/23989805/pubmed\" target=\"_blank\" id=\"23989805\">23989805</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"28203777\"></a>Tunkel AR, Hasbun R, Bhimraj A, et al. 2017 Infectious Diseases Society of America's clinical practice guidelines for healthcare-associated ventriculitis and meningitis [published online ahead of print February 14, 2017]. <i>Clin Infect Dis</i>. 2017. doi: 10.1093/cid/ciw861.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-drug-information/abstract-text/28203777/pubmed\" target=\"_blank\" id=\"28203777\">28203777</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tunkel AR, Hartman BJ, Kaplan SL, et al, &ldquo;Practice Guidelines for the Management of Bacterial Meningitis,&rdquo; <i>Clin Infect Dis</i>, 2004, 39(9):1267-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-drug-information/abstract-text/15494903/pubmed\" target=\"_blank\" id=\"15494903\">15494903</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Food and Drug Administration (FDA). Information for Healthcare Professionals: Colistimethate (marketed as Coly-Mycin M and generic products). <a href=\"http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124896.htm\" target=\"_blank\">http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124896.htm</a>. Updated August 14, 2013. Accessed January 31, 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Valachis A, Samonis G, Kofteridis DP. The role of aerosolized colistin in the treatment of ventilator-associated pneumonia: a systematic review and metaanalysis. <i>Crit Care Med</i>. 2015;43(3):527-533.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-drug-information/abstract-text/25493971/pubmed\" target=\"_blank\" id=\"25493971\">25493971</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wallace SJ, Li J, Rayner CR, Coulthard K, Nation RL. Stability of colistin methanesulfonate in pharmaceutical products and solutions for administration to patients [published online ahead of print July 7, 2008]. <i>Antimicrob Agents Chemother</i>. 2008;52(9):3047-3051.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-drug-information/abstract-text/18606838/pubmed\" target=\"_blank\" id=\"18606838\">18606838</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yapa SWS, Li J, Patel K, et al. Pulmonary and systemic pharmacokinetics of inhaled and intravenous colistin methanesulfonate in cystic fibrosis patients: targeting advantage of inhalational administration. <i>Antimicrob Agents Chemother</i>. 2014;58(5): 2570-2579.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-drug-information/abstract-text/24550334/pubmed\" target=\"_blank\" id=\"24550334\">24550334</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Young D, Zobell J, Waters C, et al, &ldquo;Optimization of Anti-Pseudomonal Antibiotics for Cystic Fibrosis Pulmonary Exacerbations: IV. Colistimethate Sodium,&rdquo; <i>Ped Pulmonol</i>, 2013, 48(1):1-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-drug-information/abstract-text/22949160/pubmed\" target=\"_blank\" id=\"22949160\">22949160</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23335739\"></a>Ziaka M, Markantonis SL, Fousteri M, et al. Combined intravenous and intraventricular administration of colistin methanesulfonate in critically ill patients with central nervous system infection. <i>Antimicrob Agents Chemother</i>. 2013;57(4):1938-1940. doi: 10.1128/AAC.01461-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-drug-information/abstract-text/23335739/pubmed\" target=\"_blank\" id=\"23335739\">23335739</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zylberberg H, Vargaftig J, Barbieux C, et al, &ldquo;Prolonged Efficiency of Secondary Prophylaxis With Colistin Aerosols for Respiratory Infection Due to <i>Pseudomonas aeruginosa</i> in Patients Infected With Human Immunodeficiency Virus,&rdquo; <i>Clin Infect Dis</i>, 1996, 23(3):641-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colistin-colistimethate-drug-information/abstract-text/8879797/pubmed\" target=\"_blank\" id=\"8879797\">8879797</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8718 Version 152.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F154558\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F154559\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F154573\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F154561\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F154569\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F154562\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F154563\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15795898\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Obesity\" href=\"#F20330556\" class=\"outlineLink\">Dosing: Obesity</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F18881845\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F154544\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F154532\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F154546\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F154545\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25475254\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F14219656\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F154539\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F154549\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F154536\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299084\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F154540\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F154542\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F5105300\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F5105303\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F5105494\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F154535\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F154548\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323078\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038587\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8718|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=colistin-colistimethate-patient-drug-information\" class=\"drug drug_patient\">Colistin (colistimethate): Patient drug information</a></li><li><a href=\"topic.htm?path=colistin-colistimethate-pediatric-drug-information\" class=\"drug drug_pediatric\">Colistin (colistimethate): Pediatric drug information</a></li></ul></div></div>","javascript":null}